Company News
Elixiron Reports 80% PET Reduction Phase 2
Elixiron Immunotherapeutics presented interim Phase 2 data for enrupatinib in seven Alzheimer’s patients, dosing 448.2 mg twice daily for 28 days.
No drug‑related serious adverse events or clinically
